Business Context and Reporting Period
This Form 6-K filing by ProQR Therapeutics N.V. covers the month of February 2026, specifically dated February 9, 2026. The report discloses a corporate governance update regarding planned changes to the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is the announcement of planned changes to the composition of the Board of Directors, as detailed in the press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, management commentary on business performance, or specific risk factors beyond the standard incorporation of the press release. No unusual items or contingencies are described in the text provided.
Key Facts for Investor Verification
- Verify the specific details of the Board composition changes in the attached press release (Exhibit 99.1).
- Confirm the effective date of the new board members or the departure of existing members.
- Note that this filing incorporates the press release into the company's active registration statements on Form F-3.